

SPEAKER BIOGRAPHIES

---LISTINGS ALPHABETICAL BY LAST NAME---

Derek C. Angus, MD, MPH, is the inaugural associate vice chancellor for health care innovation at the University of Pittsburgh Medical Center. In this role, Dr. Angus works to stimulate the fusion of multiple disciplines and skills, blending expertise in clinical care delivery with organization science, decision psychology, machine learning, Bayesian trial designs, causal inference, implementation science and behavioral economics, among others.

Dr. Angus' mandate is to enable us to learn while doing—to make smarter, faster decisions and create better integration across all of the translational, clinical, and health services and health policy domains on campus. In doing so, Dr. Angus supports the entire health sciences community in working together more effectively and in concert with UPMC.

Dr. Angus also gives equal attention to creative disruption in health sciences education. Progress in health care innovation requires the development of leaders and teams with considerable range across disciplines that have not necessarily been emphasized and have rarely been united in the same person or team. Thus, Dr. Angus works to identify opportunities to think about curricular innovations and novel training programs across the health sciences.

Dr. Angus is an internationally renowned and highly prolific scientist who has developed and led many successful multidisciplinary collaborations of basic scientists, clinicians, data scientists, economists, and behavioral and social scientists. In recent years, he has been a leader in developing and evaluating approaches that facilitate smarter decision-making and faster learning in health care, including novel Bayesian adaptive trial designs, the application of machine learning to large-scale data, and the use of behavioral economics and decision psychology to support optimal decision-making.

Dr. Angus is a Fellow of the Royal College of Physicians of the United Kingdom and has received multiple national and international honors. He completed medical school and internal medicine training at the University of Glasgow and affiliated teaching hospitals, and he completed a fellowship in critical care medicine and his MPH in health services administration at Pitt.

Willard N. Applefeld, MD is a native of Phoenix, Arizona. He received his B.S. Summa Cum Laude in Biology from the George Washington University in 2011. He received his Doctorate of Medicine Cum Laude in 2015 from the University of Maryland School of Medicine where he was elected to the Gold Humanism Honor Society and served as President of his school's chapter of Alpha Omega Alpha Honor Medical Society. Following his internship and residency in Internal Medicine on the Osler Medical Service at the Johns Hopkins Hospital from 2015-2018, he came to National Institutes of Health where he is completed a fellowship in Critical Care Medicine in June of 2021. He is currently pursuing a fellowship in Cardiovascular Disease at Duke University.

Marianna Azar is a Program Specialist with the Division of Education and Development at the Office for Human Research Protections (OHRP), U.S. Department of Health and Human Services. Before joining OHRP, Ms. Azar served as Director and Chair of the Institutional Review Boards for the New York City Department of Education. Prior to that, she was employed as a Human Research Protection Program Manager at the City University of New York Graduate Center, and as an IRB Specialist at Columbia University's Human Research Protection Office. Marianna holds a BA in Philosophy from the State University of New York at Oswego, an MA in Philosophy and a Graduate Diploma in Health

Services and Policy Research from York University in Toronto, Canada, and is also working on completing her Ph.D. in Bioethics at York University.

Jeremy Block, PhD, MPP is an adjunct professor of public and international affairs at Baruch College, CUNY. Jeremy serves as the executive director of a digital health trial focusing on population screening of genetic founder mutations at Memorial Sloan Kettering Cancer Center. Previously, Dr. Block was an Assistant Professor of Population Health Science & Policy at the Icahn School of Medicine at Mount Sinai where he was also an IRB Chair at hospitals within the Mount Sinai Health System.

Jeremy's main interests are research ethics, digital health research design and oversight, digital health product development, protecting vulnerable populations participating in research. and research during disasters & pandemics.

His background includes advising corporations and governments at the federal, state, and local level on science and technology including digital health, human subject protections, chemical & biological weapons, green and social procurement, emerging science and technology markets, and research systems at public & private universities.

He has a background in teaching ethics in public policy, bioethics, and science and technology policy at both the undergraduate and graduate level. He holds a Bachelors in Chemistry & Biology, Masters in Public Policy, and Ph.D. in Biochemistry from Duke University.

Carla Boutin-Foster, MD, is the Associate Dean, Office of Diversity Education and Research at the SUNY Downstate Health Sciences University. Dr. Boutin-Foster is a graduate of SUNY Downstate's College of Medicine. Under her leadership, the Office of Diversity Education and Research implements, sustains, and evaluates structured programs to attract and retain students, trainees, and faculty from diverse backgrounds traditionally underrepresented in medicine and biomedical research.

Dr. Boutin-Foster completed her residency in Internal Medicine at New York Presbyterian Hospital. She earned her master's degree from the Weill Cornell Medicine Graduate School of Medical Sciences in Health Services Research and Clinical Epidemiology.

She has served as the director and principal investigator of the Comprehensive Center of Excellence in Disparities Research and Community Engagement (CEDREC), which was funded by an \$8,000,000 P60 award from the National Institute on Minority Health and Health Disparities (NIMHD) of the NIH. The mission of CEDREC was to conduct innovative health disparities research, engage community partners and diversify the biomedical research pipeline.

Dr. Boutin-Foster is an alumna of the Harold Amos Medical Faculty Development Program of the Robert Wood Johnson Foundation and a Nanette Laitman Clinical Scholar in Community Health. She has written numerous peer-reviewed publications on cardiovascular disease disparities and behavioral science research.

Dr. Boutin-Foster was the chair of the Minority Health Council of the New York State Department of Health and was a member of the Public Health and Health Planning Council for New York State.

Dr. Boutin-Foster joins the faculty in the College of Medicine and works closely with the Brooklyn Health Disparities Center, under the leadership of Dr. Moro Salifu to continue her research in the areas of health disparities and community engagement.

David Fajgenbaum, MD, MBA, MSc, FCPP, is an Assistant Professor of Medicine in Translational Medicine & Human Genetics at the University of Pennsylvania, Founding Director of the Center for Cytokine Storm Treatment & Laboratory (CSTL), Associate Director, Patient Impact of the Penn Orphan Disease Center, and Co-Founder/President of the Castleman Disease Collaborative Network (CDCN). He is also the national bestselling author of 'Chasing My Cure: A Doctor's Race to Turn Hope Into Action' (<http://www.ChasingMyCure.com>) and a patient battling idiopathic multicentric Castleman disease (iMCD). He is in his longest remission ever thanks to a precision treatment that he identified, which had never been used before for iMCD.

An authority on cytokine storms and their treatment, Fajgenbaum launched the CORONA project in March 2020 to identify and track treatments for COVID-19. Today, CORONA is the world's largest database of COVID-19 treatments, including 400+ medications that have been administered to 300,000+ patients, and a go-to resource for FDA, Google Health, and others. He serves on the treatment selection committee for the NIH's ACTIV-6 trial as well as the Chair of the treatment selection committee for FDA/NIH/C-Path Institute's CURE Drug Repurposing Collaboratory (CDRC) COVID-19 inpatient trial.

One of the youngest individuals ever appointed to the faculty at Penn Medicine and in the top 1 percent youngest awardees of an NIH R01 grant, Dr. Fajgenbaum leads over 20 translational research studies, including the CORONA project and a clinical trial of the drug that is saving his life. He has published scientific papers in high-impact journals such as the New England Journal of Medicine, Blood, and Journal of Clinical Investigation, including one paper selected by STAT News in 2020 as one of the best innovations in science and medicine.

Dr. Fajgenbaum co-founded the CDCN in 2012 to accelerate research and treatments for Castleman disease through a 'Collaborative Network Approach,' a business-inspired approach to biomedical research, which has become a blueprint for advancing rare disease research. He is also dedicated to advancing drug repurposing as co-director of the advisory committee for a FDA/NIH/C-Path public-private partnership called the CURE Drug Repurposing Collaboratory and lead investigator for a collaboration with the Chan Zuckerberg Initiative to advance rare disease drug repurposing. Dr. Fajgenbaum has been profiled in a cover story by The New York Times as well as by Good Morning America, CNN, Science, Reader's Digest, Forbes 30 Under 30, and the Today Show.

Dr. Fajgenbaum received a BS in Human Sciences with Distinction from Georgetown University, where he was USA Today Academic All-USA First Team and a Quarterback on the Division I football team. He studied for an MSc in Public Health from the University of Oxford as the 2007 Joseph L. Allbritton Scholar. Dr. Fajgenbaum earned his MD from the Raymond & Ruth Perelman School of Medicine at the University of Pennsylvania, where he was a 21st Century Gamble Scholar. He received his MBA from The Wharton School, where he was awarded the Joseph Wharton Award, Core Value Leadership Award, Kissick Scholarship, Wharton Business Plan Competition Social Impact Prize, Eilers Health Care Management Award, Mandel Fellowship, and Commencement Speaker.

Robert E. Fullilove, MS, EdD is the Associate Dean for Community and Minority Affairs, Professor of Clinical Sociomedical Sciences and the co-director of the Cities Research Group at the Mailman School of Public Health, Columbia University.

Dr. Fullilove has authored numerous articles in the area of minority health. From 1995 to 2001, he served on the Board of Health Promotion and Disease Prevention at the Institute of Medicine (IOM) at the National Academy of Sciences. Since 1996, he has served on five IOM study committees that have produced reports on a variety of topics including substance abuse and addiction, HIV/AIDS, tuberculosis, and damp indoor spaces and health. In 2003 he was designated a National Associate of the National

Academies of Science. In 1998 he was appointed to the Advisory Committee on HIV and STD Prevention (ACHSP) at the Centers for Disease Control, and in July 2000, he became the committee's co-chair. Finally, between 2004-2007, he served on the National Advisory Council for the National Center for Complementary and Alternative Medicine at the National Institutes of Health [NIH]. Since 2010, he has been teaching public health courses in six New York State prisons that are part of the Bard College Prison Initiative (BPI) and serves as the Senior Advisor to BPI's public health program.

Dr. Fullilove serves on the editorial boards of the journals Sexually Transmitted Diseases, and the Journal of Public Health Policy. He has been awarded the Distinguished Teaching Award at the Mailman School of Public Health three times (in 1995, 2001, and 2013), and in May 2002, he was awarded an honorary doctorate from Bank Street College of Education.

Spencer Hey, PhD is the Co-founder and Chief Scientific Officer at Prism Analytic Technologies, Inc.

Dr. Hey received his Ph.D. in philosophy from the University of Western Ontario and a B.A. in philosophy from the University of Illinois at Chicago. He was formerly a faculty member at the Harvard Center for Bioethics and a research scientist in the Department of Medicine at the Brigham and Women's Hospital.

Dr. Hey previously held a research fellowship in the Biomedical Ethics Unit at McGill University and a visiting scholarship at the University of Oxford.

Dr. Hey spent a decade working in academia—first at McGill University before moving to Harvard. His academic research focused on developing new tools and methods to reduce inefficiencies in science and improve the quality of clinical trials. Prism's technology is grounded in the more than 60 publications that emerged from his work.

Jonathan Jackson, PhD, is the Executive Director of the Community Access, Recruitment, and Engagement (CARE) Research Center at Massachusetts General Hospital and is an Assistant Professor of Neurology at Harvard Medical School. CARE investigates the impact of diversity, inclusion, and equity on the quality of human subjects research and leverages deep community entrenchment to build trust and overcome barriers to clinical trial participation. Dr. Jackson also conducts research as a cognitive neuroscientist investigating dementing and neurological disease. He has become a well-known representative to underserved communities and dozens of affiliated organizations, especially regarding participation in clinical research. Dr. Jackson serves in an advisory capacity for several organizations focused on equity in clinical research, and has written guidance for local, statewide, and national groups on research access, engagement, and recruitment.

Yvonne Lau, MBBS, MBHL, PhD is the Director of the Division of Education and Development (DED) at the U.S. Department of Health and Human Services (HHS) Office for Human Research Protections (OHRP). She joined OHRP in June 2014 from the Office of Extramural Research of the National Institutes of Health (NIH) where she served as the Extramural Research Integrity Officer. Dr. Lau had also worked with the NIH Office of Extramural Program as Human Subjects Specialist and had served on the Institution Review Board of the MedStar Health Research Institute in Maryland. Prior to coming to the U.S., Dr. Lau was a Consultant Surgeon with the Hospital Authority of Hong Kong and founded Hong Kong's first multidisciplinary breast center and breast cancer patient support group. Dr. Lau received her medical degree from the University of Hong Kong, and is a Fellow of the Royal College of Surgeons of Edinburgh (FRCSEd) in the United Kingdom and Foundation Fellow of the Hong Kong Academy of Medicine (HKAM). She obtained her Master in Bioethics and Health Law (MBHL) and her PhD in Bioethics from the University of Otago in New Zealand.

Maggie Little, PhD is Senior Research Scholar at the Kennedy Institute of Ethics, and Professor of Philosophy at Georgetown. Her research interests include issues in reproduction, clinical research ethics, data ethics, and the structure of moral theory.

A Rhodes Scholar and fellow of the Hastings Center, she has twice served as Visiting Scholar in residence at the National Institutes of Health Department of Bioethics, and was appointed to the Ethics Committee of the American College of Obstetrics and Gynecology. She is co-founder of The Second Wave Initiative, which works to promote responsible research into the health needs of pregnant women.

In her previous role as Director of the Kennedy Institute, Dr. Little oversaw a time of transformative development, including the launch of the world's first Introduction to Bioethics MOOC in April 2014; the inauguration of Conversations in Bioethics, an annual campus-wide event focused on a critical issue in bioethics; the deployment of a series of experimental undergraduate courses utilizing project-based learning and design studio methods. Dr. Little is founder and Director of EthicsLab, a unique team of Philosophers and Designers at Georgetown University that develops new methods to help people build ethical frameworks to better address real-world problems. Ethics Lab works to help surface the moral values at stake in emerging, complex issues, including data ethics and AI, to help build responsible progress. She is a founding co-chair of the Tech and Society Initiative at Georgetown.

Jerry A. Menikoff, M.D., J.D., is the Director of the Office for Human Research Protections (OHRP), a component of the U.S. Department of Health and Human Services (HHS). This office is responsible for protecting the rights, welfare, and well-being of subjects involved in research conducted or supported by HHS. In addition, OHRP provides leadership in the protection of subjects by providing clarification and guidance, developing educational programs and materials, and maintaining regulatory oversight.

Prior to joining OHRP, Dr. Menikoff served as the director of the National Institutes of Health (NIH) Office of Human Subjects Research, responsible for day-to-day oversight of the NIH intramural research program's human research protection program, including policy development and educational activities.

Dr. Menikoff held several academic positions prior to his government service. He served for nine years as the chair of the human subjects committee and the hospital ethics committee at the University of Kansas Medical Center. He also was on the faculty of schools of law at the University of Chicago and other universities. Immediately prior to coming to the federal government, he was Associate Professor of Law, Ethics and Medicine at the University of Kansas.

Dr. Menikoff's research interests have concentrated on bioethics in general, and more particularly on the ethics of research with human subjects. Dr. Menikoff is the author of *Law and Bioethics: An Introduction* (Georgetown University Press) and *What the Doctor Didn't Say: The Hidden Truth about Medical Research* (Oxford University Press).

Dr. Menikoff received his undergraduate degree from Harvard University (magna cum laude in Mathematics, 1973), and also received in 1977 a J.D. (magna cum laude; Editor and Officer of the Harvard Law Review) and M.P.P. (Public Policy) from Harvard. Dr. Menikoff earned an M.D. in 1986 from Washington University (St. Louis).

Michelle Meyer, JD, PhD is an Associate Professor at Geisinger, where she co-directs an interdisciplinary lab that investigates judgments and decision-making related to research, innovation, and healthcare. She is also Associate Director for Research Ethics at Geisinger, chairs Geisinger's IRB Leadership Committee, directs its Research Ethics Advice and Consulting Service, and serves on its AI Governance Committee. Finally, she is the Faculty Co-Director of the Behavioral Insights Team (BIT) in

Geisinger's Steele Institute for Health Innovation. The BIT designs, implements, and rigorously evaluates provider- and patient-facing "nudges" that aim to make healthy choices easier and also investigates acceptability of nudges to stakeholders. She is also an Assistant Professor of Bioethics, by courtesy, in the Geisinger Commonwealth School of Medicine.

Her writing has appeared in leading journals of bioethics (American Journal of Bioethics, HastingsCenter Report, Kennedy Institute of Ethics Journal), law (Harvard Law Review, Administrative Law Review), and science (Science, Nature, PNAS), as well as in popular media outlets (New York Times, Slate, Wired, Los Angeles Times, and Forbes.com). She has served on numerous boards and commissions, including National Academies study committees and working groups, an American Psychological Association blue ribbon commission, the editorial board of Advances in Methods and Practices in Psychological Science, the Board of Directors of Open Humans Foundation (formerly PersonalGenomes.org), and the Ethics and Compliance Advisory Board of PatientsLikeMe. She is a Team Scientist with Wharton's Behavior Change for Good Initiative.

Before joining Geisinger, Michelle was an Assistant Professor and Director of Bioethics Policy in the Clarkson University–Icahn School of Medicine at Mount Sinai School of Medicine Bioethics Program and Adjunct Faculty at Albany Law School; an Academic Fellow at the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School; a Greenwall Fellow in Bioethics and Health Policy at The Johns Hopkins and Georgetown Universities; and a Research Fellow at the John F. Kennedy School of Government at Harvard. She earned a Ph.D. in religious studies, with a focus on applied ethics, from the University of Virginia and a J.D. from Harvard Law School, where she was an editor of the Harvard Law Review. Following law school, she clerked for Judge Stanley Marcus of the U.S. Court of Appeals for the Eleventh Circuit. She graduated summa cum laude from Dartmouth College.

Mangala Narasimhan, DO, FCCP, FASM, FACP is the Senior Vice President and Director, Critical Care Services, at Northwell Health.

As director of Critical Care Services, Dr. Narasimhan works with all of Northwell Health's clinical, operational and critical care leadership to help drive greater consistency and standardization across the health system's Critical Care Services and related operations. Her team is highly focused on improving quality and patient safety outcomes.

Dr. Narasimhan also serves as an attending physician in the Division of Pulmonary, Critical Care and Sleep Medicine, medical director of Northwell's Acute Lung Injury Center/VV ECMO program and a professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. She is a recognized leader who is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.

At Northwell, Dr. Narasimhan has helped widen access to critical care trained physicians at community hospitals that do not have on-site intensivists and has helped launch telehealth services in many of our ICUs. In addition, she co-founded the ECMO-to-go program in collaboration with Northwell's Cardiothoracic Surgery services. During the COVID-19 pandemic, Dr. Narasimhan cared for the most severely ill patients at Long Island Jewish Medical Center and North Shore University Hospital, sites that experienced significant patient surge.

Throughout her tenure at Northwell, Dr. Narasimhan has trained hundreds of physicians, advanced clinical providers and residents. In 2017, she received the Northwell Health Teacher of the Year Award and she was named a Regional President's Award finalist for Physician of the Year in 2020. She has more than 65 publications in various topics of critical care medicine and a large number of regional, national

and international presentations. Dr. Narasimhan also serves as a co-director for the American College of Chest Physicians (ACCP) course in Critical Care Ultrasonography and director of the Chest Course for Board Review in Advanced Echocardiography. She sits on the Education Committee at Chest and is the chairperson for the Live Learning Subcommittee.

Dr. Narasimhan holds a bachelor's degree from Barnard College, a Master's Degree from CUNY in Molecular Biology and a medical degree from the University of Health Sciences in Kansas City. She completed her residency, chief residency and fellowship at Beth Israel Medical Center.

Harlan Pruden (nēhiyo/First Nations Cree), works with and for the Two-Spirit community locally, nationally and internationally. Currently, Harlan is the Indigenous Knowledge Translation Lead at Chee Mamuk, an Indigenous health program at BC Centre for Disease Control and is also a co-founder of the Two-Spirit Dry Lab, Turtle Island's first research group or lab that exclusively focuses on Two-Spirit people, communities and/or experiences. Additionally, Harlan is the co-chair of the BCCDC's COVID-19 Indigenous Knowledge Translation Working Group. As a Ph.D. student in the FHS, Harlan explore how (and if) Two-Spirit is facilitator of health and wellbeing for Indigenous sexual and/or gender peoples and communities. Harlan is also the Managing Editor of the Two-Spirit Journal and an Advisory Member for the Canadian Institutes of Health Research's Institute of Gender and Health. Before relocating to Vancouver in 2015, Harlan was co-founder and a Director of NYC community based organization, the NorthEast Two-Spirit Society and was a President Obama appointee to the US Presidential Advisory Council on HIV/AIDS (PACHA) and provided advice, information, and recommendations to the Secretary of Health & Human Services and the White House. (In December 2018, Harlan was (happily) fired and/or dismissed from PACHA by Mr. Trump via Fedex.)

Travis Salway, PhD (he/him) , Assistant Professor, Faculty of Health Sciences, is a settler of German and English descent and queer man from Ohio (Shawnee, Myaamia/Miami, Kaskaskia, and Kiikaapoi territories), currently living as an uninvited guest on unceded territories of the x^wməθkwəyəm (Musqueam), Skwxwú7mesh (Squamish), and Səlílwəta? (Tsleil-Waututh) First Nations. He is a social epidemiologist who works to understand and improve the health of Two-Spirit, lesbian, gay, bisexual, transgender, and queer (2S/LGBTQ) populations. Since 2019, Travis is an Assistant Professor in the Faculty of Health Sciences at Simon Fraser University and conducts research in affiliation with the BC Centre for Disease Control and the Centre for Gender and Sexual Health Equity.

Alex C. Spyropoulos, MD, FACP, FCCP, FRCPC received his medical degree from the University of Pennsylvania School of Medicine in Philadelphia in 1992. He completed his internship and residency in internal medicine at the University of New Mexico Health Sciences Center in Albuquerque, NM. He is board certified in Internal Medicine.

Dr. Spyropoulos was Founder and former medical director of the Clinical Thrombosis Center in Albuquerque, New Mexico. He is co-chair of the Council on Leadership of Thrombosis at Northwell Health System. He is also a professor for the Center for Heart and Lung Research as part of the Feinstein Institutes of Medical Research. He is a Fellow of the American College of Physicians, American College of Chest Physicians, International Academy of Clinical and Applied Thrombosis/Haemostasis, and the Royal College of Physicians, Canada.

He has been involved as principal investigator, Scientific Committee member, Steering Committee member, or member of Data Safety Monitoring Board in multiple international, multicenter randomized trials in thrombosis. He is a Steering Committee member of the NHLBI BRIDGE and Kids DOTT studies and the CIHR PAUSE trial, He is a founding member of ATLAS, a US-based ARO-CRO in thrombosis-related research. He is a panel member of a US national experts consensus group for clinical excellence in thrombosis management, a member of the Anticoagulation Forum and the Thrombosis/Haemostasis

Society of North America, co-Chair of the Scientific Standardization Committees of Predictive Variables and Perioperative Thrombosis and Haemostasis as part of the International Society of Thrombosis and Haemostasis, and co-author for the 8th and 9th American College of Chest Physician (ACCP) Antithrombotic Guidelines, the 2008 International Consensus Statement Guidelines and senior author for the 2013 International Consensus Statement on venous thromboembolic disease. He was reviewer for the 2014 ESC Guidelines on Pulmonary Embolism. He is presently a panelist for the 2016/2017 ACCP Antithrombotic Guidelines on Perioperative Anticoagulant Management.

Dr. Spyropoulos' articles, letters, and editorials have been published in over 160 peer-reviewed journals including The New England Journal of Medicine, Blood, Circulation, American Journal of Hematology, American Journal of Medicine, Chest, Thrombosis Haemostasis, American Journal of Cardiology, Journal of Thrombosis and Haemostasis, Journal of the American College of Cardiology, Clinical Applied Thrombosis Haemostasis, and Thrombosis Research. He is Section Editor for Thrombosis and Haemostasis, and is on the editorial staff for Thrombosis Research and Hospital Medicine. He is a reviewer for many journals.

Adey Tsegaye, MD is Associate Professor of Medicine at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, as well as the Director of the Medical Intensive Care Unit at Long Island Jewish Medical Center.

Dr. Tsegaye graduated from the University of Connecticut Medical School and completed residency and fellowship training at Beth Israel Medical Center in Manhattan. She worked as an ICU attending at Saint Barnabas Hospital in the South Bronx for four years before joining Northwell Health. Dr. Tsegaye is board certified in internal medicine, critical care medicine, pulmonary disease, and sleep medicine. She completed her fellowship at Clinilabs Inc. Sleep Disorder Institute. As both a pulmonary expert and ICU Director, Dr. Tsegaye has been instrumental in her institution's COVID-19 response.
